BioCentury
ARTICLE | Politics, Policy & Law

FDA’s future & China Summit Preview

Priorities for FDA’s next commissioner, plus expectations for the COVID-19 vaccine panel

October 20, 2020 1:44 AM UTC

Should a new FDA commissioner be tapped to lead the agency after the U.S. presidential election, her top priority should be to work to restore confidence in the regulatory body’s independence, says BioCentury Washington Editor Steve Usdin. On BioCentury’s latest weekly podcast, Usdin and colleagues discuss the challenges FDA’s next leader will face, preview this week’s advisory committee meeting on COVID-19 vaccines and explore the questions around access to experimental therapies raised by former N.J. Gov. Chris Christie’s treatment for the coronavirus. 

Joshua Berlin, BioCentury head of business development, joins the podcast to preview the panels and participants for this year’s seventh BioCentury-BayHelix China Healthcare Summit...